Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Molecular Diagnostic Reimbursement
Companies are facing significant challenges in gaining provider acceptance and reimbursement for molecular diagnostics, which are the hallmark of personalized medicine. Steven Burrill, CEO of Burrill & Company, even likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.” Some companies are prevailing, however, through strategies that include obtaining a dedicated current procedural terminology (CPT) code, gaining acceptance of diagnostics as a standard of care, and forming partnerships with the pharmaceutical industry. Others are concentrating efforts on developing diagnostics for the ex-U.S. market. How is your company handling this issue?